Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00197171 | Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine | PHASE3 | COMPLETED | 143 | — | — | Sep 1, 2003 | Dec 1, 2003 | Sep 7, 2016 | 2 | Australia |
| Name | Type | Description |
|---|---|---|
| Combined Hepatitis A and B vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Subjects who received GSK Biologicals' combined hepatitis A and B vaccine in the primary study (HAB-082). Subjects were aged 12 to 15 years at the time of the first vaccination.